论文部分内容阅读
目的 :探讨原发性肝癌 (HCC)患者治疗前、后的血清可溶性上皮钙粘蛋白 (SE- Cadherin)水平变化。方法 :用酶联免疫吸附双抗体夹心法检测 2 6例 HCC患者治疗前、后的血清 SE- Cadherin水平及 2 1例正常健康人血清 SE- Cad-herin水平。结果 :原发性肝癌患者治疗前血清 SE- Cadherin水平明显高于治疗后 ,其差异有显著性意义 (P<0 .0 1)。而正常健康人血清 SE- Cadherin水平不高。结论 :血清 SE- Cadherin水平的测定可作为原发性肝癌的诊断及疗效观察指标 ,并有可能成为预后评判和复发指标。
Objective: To investigate the changes of serum soluble cadherin (SE-Cadherin) levels in patients with primary hepatocellular carcinoma (HCC) before and after treatment. Methods: Serum levels of SE-Cadherin and serum levels of SE-Cad-herin in 21 HCC patients before and after treatment were detected by enzyme linked immunosorbent assay (ELISA) double antibody sandwich method. Results: The serum level of SE-Cadherin in patients with primary liver cancer before treatment was significantly higher than that after treatment, the difference was significant (P <0.01). However, the serum level of SE-Cadherin in normal healthy people is not high. Conclusion: The serum level of SE-Cadherin can be used as a diagnostic and therapeutic index for primary hepatocellular carcinoma and may be an index of prognosis and recurrence.